Popular Science: A $25 whistle-like tool could be a game changer for COPD patients
The PEP Buddy is cheap, uses no electronics, and could help regulate breathing for COPD sufferers
One in 10 adults suffer from the debilitating effects of chronic obstructive pulmonary disease (COPD). Research around a new breathing device developed by pulmonologists at the University of Cincinnati offers promise for improving their lives.
The new device not only improves symptoms of breathlessness and quality of life for people with COPD, it also offers benefits for people dealing with stress and anxiety and those practicing mindfulness, meditation or yoga.The research was published in the journal Respiratory Care and covered in an article published by Popular Science.
The outlet reported that a team at the University of Cincinnati has created a new positive-expiratory pressure (PEP) device roughly the size and shape of whistle that attaches to a lanyard for users to keep on them during their everyday activities. Unlike existing PEP products that are often handheld, bulky, and expensive, Muhammad Ahsan Zafar and Ralph Panos’ PEP Buddy aid only costs around $25, and includes no electronics. Zafar, MD, and Panos, MD, are both in the Department of Pulmonary Critical Care and Sleep Medicine at the UC College of Medicine.
The article goes on to say because of their respiratory system degradation and weaker air tubes, it often takes COPD sufferers longer to exhale while breathing. When their breath quickens, such as during physical activities or while stressed, more and more air stays within the lungs, causing “dynamic hyperinflation” that leads to breathlessness and lower oxygen levels. This compounds over time, and often restricts or discourages further physical movement and exertion, which then can worsen existing COPD symptoms.
To combat these problems, users put the device in their mouth just as they would a whistle when needed, then breathe through their nose and exhale through the product. PEP Buddy’s design simply relies on creating a slight back pressure while users breathe out, thus slowing down their exhalations to better regulate air flow. In their studies, Zafar and Panos found that around 72% of patients utilizing PEP Buddy over a two-week period reported a “significant impact” in reducing shortness of breath while also improving their everyday living. What’s more, over a third of those participating in the study showed no signs of dropping oxygen levels while PEP Buddy was in use.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Local 12: Music creation's impact on the brain after cancer
August 4, 2021
UC researchers launched a new study looking treating a common brain problem that results after therapy for cancer.
WLWT: COVID-19 vaccine distribution in Ohio
January 11, 2021
COVID-19 vaccine providers across Ohio will soon get better guidance about the next steps for getting shots into arms. Brett Kissela, MD, spoke to WLWT-TV, Channel 5 and said the benefits of the vaccine outweigh any potential side effects.
What's Happening in Health: RNA treatment for brain cancer
May 18, 2021
UC's Daniel Pomeranz Krummel, PhD, discusses new brain cancer research with Liz Bonis on Local 12's What's Happening in Health program.
'I'm a believer': UC dean for research takes next step in COVID-19 trial
January 8, 2021
Brett Kissela, MD, senior associate dean for clinical research at the UC College of Medicine and chief of research services at UC Health, learned he received the placebo in the Moderna vaccine clinical trial. He then received the real vaccine to show that he believes in the science.
MedPage Today: Preop chemotherapy misses mark in pancreatic cancer
January 21, 2021
UC research, published in JAMA Oncology, shows that chemotherapy before surgery for some pancreatic cancer patients may not improve survival rates.
COVID-19 Conversations Podcast: Participation in vaccine trial
December 17, 2020
UC's Brett Kissela, MD, discusses participating in the Moderna vaccine trial on an African Alliance podcast.
WVXU: Does your spinal fluid show if you have a tumor?
November 9, 2020
University of Cincinnati researchers are starting a clinical trial to determine if they can detect brain cancer in spinal fluid.
US News & World Report: Immunotherapy and cancer, COVID-19
July 21, 2020
National media outlets report on new UC findings that show immunotherapy will not worsen complications for patients who have cancer and COVID-19.
Drugs.com: Effect of cancer treatment on COVID-19 mortality
September 22, 2020
Drugs.com covers UC research looking at mortality in patients with cancer and COVID-19.
WVXU: Certain cancer treatments & COVID-19 could lead to death
September 22, 2020
WVXU reports on a University of Cincinnati study showing cancer patients undergoing a combination of chemotherapy and immunotherapy one to three months before a COVID-19 diagnosis have a greater risk of death than patients who haven't undergone cancer treatment in the past year.